Outcome Predictors After Successful Intra-Arterial Therapy for Acute Ischemic Stroke

Objective: To study the factors that might predict outcome in stroke patients who undergo endovascular therapy with successful Background: Timely recanalization after endovascular therapy for acute ischemic stroke is the prototype predictor for good Other factors that might affect recovery are not well documented. Method: A single center retrospective database review identified stroke patients who underwent successful intra-arterial therapy (TICI Score . Demographic, clinical, radiographic, and procedural variables of these patients were included in logistic statistical analysis using t-test and Chi-square test to study their effects on functional outcome. Results: Out of 296 patients, 129 (43.5[percnt]) had successful recanalization. Of those patients, 68 (52.7[percnt]) had good functional outcome defined as mRS 0-2, and 55 (42.6[percnt]) had poor outcome (mRS u003e2). Six patients were lost during follow-up. Onset to groin puncture average time was 352 minutes, while the mean procedure duration was 108 minutes.When comparing groups patients with good functional outcome were younger (mean age 59 years compared to 66 years, p 0.0116), and had less severe stroke (mean NIHSS score 13 compared to 19, p u003c0.0001). Employment of stent retrievers was associated with good outcome (p 0.036), while general anesthesia and symptomatic intracerebral hemorrhage were associated with poor outcome (p 0.01, and 0.005, respectively).On multivariate analysis; age (p 0.001), NIHSS score (pu003c0.0001), and use of stent retrievers (p 0.0264) remained as independent predictors for good outcome, whereas general anesthesia (p 0.005) and symptomatic intracerebral hemorrhage (p 0.0002) independently predicted poor outcome. Conclusion: Age, NIHSS score, use of stent retrievers, mode of anesthesia, and symptomatic ICH might affect functional outcome in stroke patients who achieve successful recanalization via intra-arterial therapy. Prospective studies, or a meta-analysis of sub-groups in the recently published prospective trials are needed to confirm the association between those factors, or others, and functional Disclosure: Dr. Noufal has nothing to disclose. Dr. Mankad has nothing to disclose. Dr. Lakraj has nothing to disclose. Dr. Cox has nothing to disclose. Dr. Shirilla has nothing to disclose. Dr. Sattar has nothing to disclose. Dr. Wazni has nothing to disclose. Dr. Sallowm has nothing to disclose. Dr. Lynch has nothing to disclose. Dr. Zaidat has received personal compensation for activities with Stryker, Covidien, and Penumbra as a consultant.